HeadSafe taps HeadFirst Dx to speed U.S. rollout of Nurochek-Pro

HeadSafe named HeadFirst Dx as its U.S. commercialization and distribution partner to expand access to its FDA-cleared portable brain assessment system. The deal is aimed at speeding adoption of objective concussion evaluation tools across clinics, hospitals, sports medicine programs and athletic organizations nationwide.

Why it matters: - The partnership gives HeadSafe a nationwide commercialization channel for Nurochek-Pro, its FDA-cleared portable brain assessment system. - Broader distribution could expand access to objective brain function data for concussion evaluation, which is still often based on subjective assessment. - The arrangement is designed to reach healthcare providers, hospitals, sports medicine programs, education groups and athletic organizations across the U.S.

What happened: - HeadSafe appointed HeadFirst Dx as its U.S. commercialization and distribution partner on Sept. 17, 2026. - The companies said the deal supports the national rollout of Nurochek-Pro. - HeadFirst Dx will lead U.S. commercialization efforts for the product.

The details: - Nurochek-Pro uses electroencephalogram, or EEG, together with visual evoked potential, or VEP, technology. - The system is designed to deliver objective brain function data in about two minutes. - Nurochek-Pro requires no baseline test. - HeadSafe said the system is intended for use in clinical and point-of-care settings. - HeadFirst Dx is a nationwide medical technology commercialization and distribution company focused on concussion care. - The company says its team has more than 30 years of combined experience in diagnostics, medical devices and healthcare commercialization. - HeadFirst Dx supports manufacturers through physician engagement, clinical education, market development and customer support. - HeadSafe said the partnership strengthens its U.S. commercial presence and adds infrastructure for adoption, training and ongoing use of Nurochek-Pro. - HeadSafe directs readers to more information.

Between the lines: - The deal signals an attempt to move concussion assessment away from purely subjective evaluation and toward standardized brain function data. - HeadSafe is pairing a cleared medical device with a specialist distributor rather than building U.S. reach on its own. - HeadFirst Dx is positioning itself as a commercialization partner for neurological diagnostic tools, not just a sales channel.

What's next: - HeadFirst Dx will work to drive adoption of Nurochek-Pro across the U.S. - HeadSafe said the partnership should help expand clinician and athletic trainer access to objective brain assessment technology. - The companies are likely to focus on sales, training and market development as the rollout expands.